HC Wainwright Forecasts Armata Pharmaceuticals Q3 Earnings

Key Points

• HC Wainwright lowered Armata Pharmaceuticals’ Q3 2026 EPS forecast to a loss of $0.57 per share from $0.53 previously. The firm also projects losses of $0.57 per share in Q4 2026 and $2.04 per share for FY2027.
• Armata’s latest quarterly results beat expectations, with an EPS loss of $0.27 versus the $0.44 consensus estimate and revenue of $2.51 million compared with expectations of $0.40 million.
• Analyst sentiment remains generally positive, with two Buy ratings and one Hold rating producing a Moderate Buy consensus and an average price target of $15.00. The stock recently opened at $4.56, well below its 12-month high of $16.34.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Armata Pharmaceuticals in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.57) per share for the quarter, down from their prior forecast of ($0.53). The consensus estimate for Armata Pharmaceuticals' current full-year earnings is $0.50 per share. HC Wainwright also issued estimates for Armata Pharmaceuticals' Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at $0.50 EPS and FY2027 earnings at ($2.04) EPS.

Separately, Zacks Research raised Armata Pharmaceuticals to a "hold" rating in a report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $15.00.

Armata Pharmaceuticals Stock Performance

Armata Pharmaceuticals stock opened at $4.56 on Monday. Armata Pharmaceuticals has a 12 month low of $2.40 and a 12 month high of $16.34. The stock has a fifty day simple moving average of $5.58 and a two-hundred day simple moving average of $8.12. The firm has a market cap of $167.40 million, a price-to-earnings ratio of -0.60 and a beta of 1.30.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.17. Armata Pharmaceuticals had a negative return on equity of 12.24% and a negative net margin of 3,467.04%.The business had revenue of $2.51 million for the quarter, compared to analysts' expectations of $0.40 million.

Institutional Investors Weigh In On Armata Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Deutsche Bank AG bought a new position in shares of Armata Pharmaceuticals in the 2nd quarter worth approximately $78,000. Jane Street Group LLC purchased a new position in shares of Armata Pharmaceuticals in the fourth quarter worth approximately $108,000. Bank of America Corp DE grew its position in Armata Pharmaceuticals by 233.2% during the first quarter. Bank of America Corp DE now owns 11,714 shares of the company's stock valued at $120,000 after buying an additional 8,198 shares during the period. Millennium Management LLC bought a new stake in Armata Pharmaceuticals during the fourth quarter valued at approximately $164,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Armata Pharmaceuticals during the fourth quarter valued at approximately $177,000. Hedge funds and other institutional investors own 3.57% of the company's stock.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company's proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata's pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source